Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Short-term effects of pulmonary rehabilitation on asthma control in patients with moderate-severe unstable asthma Source: International Congress 2019 – Hot topics in pulmonary rehabilitation Year: 2019
Predictors of exercise-induced airways obstruction in patients with mild asthma. Source: Virtual Congress 2020 – Exploring exercise responses in respiratory diseases Year: 2020
Effect of dupilumab on severe exacerbations in asthma patients with and without lung function improvements Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Follow-up of patients with severe asthma by noninvasive parameters of airway inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 52s Year: 2001
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019 Year: 2020
Improvement in symptoms, wheezing and pulmonary function tests of asthmatic patients due to application of GINA in their treatment Source: Eur Respir J 2006; 28: Suppl. 50, 842s Year: 2006
Severe outcomes of COVID-19 among patients with COPD and asthma Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020 Year: 2021
“App” for uncontrolled moderate-severe asthma patients follow-up Source: International Congress 2017 – Biomarker-based asthma control Year: 2017
Clinical markers of disease severity in the assessment of airway inflammation in patients with persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 335s Year: 2001
Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018
Long-term benefits of pulmonary rehabilitation in patients with chronic asthma Source: Eur Respir J 2002; 20: Suppl. 38, 454s Year: 2002
The association between airway and systemic eosinophilia and symptoms and exacerbations differ between asthma and COPD patients Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020
Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Tiotropium reduces asthma exacerbations in asthmatic patients with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Asthma patients adjust their maintenance treatment late in response to worsening asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 7s Year: 2005